Latest news

• 14 January 2022

  HAS launches as an independent business

  Biasca, Switzerland – HAS Healthcare Advanced Synthesis SA...
• 14 January 2022

  Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes

  - Strategy focuses on developing and commercializing a...
• 21 December 2021

  Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements

  Lugano, Switzerland, December 21, 2021 - Helsinn Group...